PatientsVille.com Logo

MELAENA and Diclofenac

PatientsVille

MELAENA Symptoms and Causes

A bowel movement is the last stop in the movement of food through your digestive tract. Your stool passes out of your body through the rectum and anus. Another name for stool is feces. It is made of what is left after your digestive system (stomach, small intestine, and colon) absorbs nutrients and fluids from what you eat and drink.

Sometimes a bowel movement isn't normal. Diarrhea happens when stool passes through the large intestine too quickly. Constipation occurs when stool passes through the large intestine too slowly. Bowel incontinence is a problem controlling your bowel movements. Other abnormalities with bowel movements may be a sign of a digestive problem.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for MELAENA

MELAENA treatment research studies

Diclofenac clinical trials, surveys and public health registries


Find Drug Side Effect reports



Diclofenac Side Effects

Renal Failure Acute (154)
Abdominal Pain (139)
Diarrhoea (136)
Vomiting (128)
Dyspnoea (103)
Haemoglobin Decreased (103)
Gastrointestinal Haemorrhage (102)
Nausea (88)
Blood Creatinine Increased (88)
Anaemia (86)
Malaise (83)
Dehydration (82)
Pruritus (79)
Abdominal Pain Upper (77)
Blood Urea Increased (76)
Dizziness (72)
Gastric Ulcer (68)
Gastrointestinal Disorder (68)
Haematemesis (64)
Anaphylactic Reaction (62)
Pyrexia (61)
Erythema (60)
Fatigue (60)
Pain (60)
Hypotension (57)
Melaena (56)
Embolia Cutis Medicamentosa (54)
Chest Pain (54)
Arthralgia (53)
Rash (53)
Oedema Peripheral (51)
Asthenia (50)
Loss Of Consciousness (49)
Alanine Aminotransferase Increased (49)
Fall (48)
Headache (47)
Blood Alkaline Phosphatase Increased (47)
Metabolic Acidosis (46)
Gastritis (46)
Renal Failure (45)
Cardiac Arrest (44)
Confusional State (43)
Back Pain (43)
C-reactive Protein Increased (43)
Convulsion (43)
Urticaria (43)
Blood Pressure Decreased (41)
Weight Decreased (41)
Peritonitis (41)
Aspartate Aminotransferase Increased (40)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

MELAENA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Endoscopic Evaluation of Lower Gastrointestinal Bleeding (GIB) in Patients Presenting With Melena
Condition: Gastrointestinal Hemorrhage
Intervention: Procedure: Capsule endoscopy
Outcome Measure: Diagnostic yield of capsule endoscopy as the primary investigation for small bowel after negative esophagogastroduodenoscopy
2 Recruiting Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation
Conditions: Chronic Pancreatitis;   Diabetes Mellitus
Intervention: Device: Closed Loop Insulin
Outcome Measures: Mean Blood Glucose Value;   Continuous glucose monitoring sensor data;   Random morning C-peptide;   Random morning glucose;   Mixed meal tolerance test;   Daily insulin needs
3 Recruiting Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
Conditions: Pancreatitis;   Diabetes
Interventions: Drug: Sitagliptin;   Drug: Placebo
Outcome Measures: Insulin independence;   Insulin secretion;   Partial Graft Function
4 Recruiting Tranexamic Acid for Upper Gastrointestinal Bleeding
Condition: Acute Upper Gastrointestinal Hemorrhage
Interventions: Drug: Early intravenous tranexamic acid administration;   Drug: placebo
Outcome Measures: Proportion of patients requiring early endoscopic treatment;   Endoscopic signs of bleeding;   Length of stay;   Need for urgent endoscopy;   Endoscopic procedure time/difficulty;   Need for transfusion;   Need for surgery/angiographic intervention;   rate of recurrent bleeding;   death of any cause;   thromboembolic complications
5 Recruiting Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.
Condition: Upper Gastrointestinal Bleeding
Interventions: Drug: Erythromycin;   Drug: Metoclopromide
Outcome Measures: 1. Wither erythromycin, metoclopromide vs control can enable visualization of the entire gastric mucosa .;   2. Wither erythromycin, metoclopromide vs control can improve the quality of stomach and duodenum visualization: using the scoring system by Fossard et al;   Ability to identify the source of bleeding;   Need for second-look endoscopy;   Mean number of blood units transfused;   All cause mortality
6 Not yet recruiting The Use of Hexacapron in Upper Gastrointestinal Bleeding
Conditions: Upper Gastrointestinal Bleeding;   Hexacapron;   Hemostasis;   Rebleeding;   Mortality
Interventions: Drug: Hexacapron( Tranexamic acid);   Drug: esomeprazole
Outcome Measures: Prevention of rebleeding manifested as hematemesis, melena and drop in hemoglobin level by 2g% within 24 hours after therapeutic endoscopy;   Rebleeding, need for surgery , 30 day mortality
7 Unknown  Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
Condition: Acute Idiopathic Thrombocytopenic Purpura
Intervention:
Outcome Measure:
8 Recruiting Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion
Condition: HELICOBACTER INFECTION
Interventions: Biological: Pylopass;   Biological: Placebo
Outcome Measures: Efficacy of Pylopass to reduce H pylori load by urease breath test (UBT);   Symptoms, using the Gastrointestinal Symptom Rating Scale (GSRS)
9 Unknown  Peptic Ulcer Disease in Ischemic Heart Patients Taking Aspirin and Clopidogrel With or Without Proton Pump Inhibitor
Conditions: Peptic Ulcer;   Ulcer Complications
Interventions: Drug: lansoprazole;   Drug: aluminum hydroxide 334 mg and Mg hydroxide 166 mg
Outcome Measures: The primary end point is the occurrence of clinical upper GI events (symptomatic ulcer and ulcer complications-bleeding, perforation, or obstruction);   The secondary end point is occurrence of dyspepsia, asymptomatic gastroduodenal ulcers
10 Recruiting Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Condition: Pancreatectomy for Chronic Pancreatitis
Interventions: Drug: Reparixin;   Drug: Placebo
Outcome Measures: The proportion of insulin-independent patients following IAT;   Area Under the Curve (AUC) for the serum C-peptide level;   Average daily insulin requirements;   Time course from basal to 240 min of glucose derived from the MMTT.;   Time course from basal to 240 min of C-peptide derived from the MMTT.;   Time course from basal to 240 min of insulin derived from the MMTT.;   β-cell function;   Proportion of patients with an HbA1c <6.5%;   Cumulative number of severe hypoglycemic events;   Proportion of patients with an HbA1c <6.5% at day 365+14 AND are free of severe hypoglycemic events from day 75+14 to day 365+14 inclusive;   Incidence and severity of Adverse Events and Serious Adverse Events;   Proportion of patients falling into one of the following malnutrition risk levels (poor prognosis, significant risk, increased risk, normal) according to pre-albumin level;   Proportion of patients falling into one of the following levels of steatorrhea severity;   Cumulative number of episodes of documented hypoglycemia (documented symptomatic; asymptomatic);   Cumulative number of diabetic ketoacidosis-related events
11 Unknown  Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
Condition: Nonvariceal Upper Gastrointestinal Bleeding
Interventions: Drug: Intravenous Omeprazole;   Drug: Oral Rabeprazole
Outcome Measure: This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on bleeding control in patients with mild to moderate non-variceal UGIB.
12 Not yet recruiting Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
Condition: Hepatic Encephalopathy
Interventions: Drug: Lactulose;   Drug: L-ornithine L-aspartate;   Drug: Rifaximin;   Drug: Placebo
Outcome Measures: Development of clinical hepatic encephalopathy;   Development of minimal hepatic encephalopathy
13 Recruiting Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Intranasal Glucagon;   Drug: Glucagon
Outcome Measures: Area under the curve from time zero to the last quantifiable concentration (AUC0-t) of glucagon;   Maximum observed concentration (Cmax) of glucagon;   Time to maximum concentration (tmax) of glucagon;   Nasal and non-nasal effects/symptoms;   Maximum concentration (Cmax) of glucose;   Time to maximum concentration (Tmax) of glucose;   Area under the effect concentration time curve (AUEC0-1.5) of glucose from time zero up to 90 minutes;   The proportion and 99% confidence interval of the proportion of participants achieving at least a 25 mg/dl rise in blood glucose above basal level;   Time to achieving ≥25 mg/dl rise in plasma glucose above basal level
14 Available Islet Transplant for Type 1 or Surgical Diabetes
Conditions: Type 1 Diabetes Mellitus;   Hypoglycemia;   Labile Diabetes;   End-stage Renal Disease
Intervention: Biological: Allogeneic islets of Langerhans
Outcome Measure: